Glucocorticoid-induced osteoporosis

Pathogenesis, prevention and treatment

P. S. Gulko, A. L. Mulloy

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

Glucocorticoids (GC) are widely used for anti-inflammatory and immunossupressive therapy. Thirty to 50% of GC-treated patients develop osteoporosis. Potential mechanisms of GC-induced osteoporosis (GC-OP) include abnormalities in calcium balance, vitamin D metabolism, parathyroid hormone release and activity, prostaglandin E 2 and cytokine synthesis, interference with c-fos and p-53 expression in osteoblasts, and hypogonadism. Early diagnosis and detection of patients at risk are accomplished with rapid, safe and non-invasive bone density measurements. Preventive measures include maintaining a positive calcium balance, vitamin D supplementation (if indicated) and treatment of hypogonadism. The shortest duration and the smallest doses possible of GC for a particular condition are advisable. For high-risk patients and those with established GC-OP calcitonin or bisphosphonate therapy is recommended.

Original languageEnglish (US)
Pages (from-to)199-206
Number of pages8
JournalClinical and Experimental Rheumatology
Volume14
Issue number2
StatePublished - Mar 1 1996

Fingerprint

Glucocorticoids
Osteoporosis
Hypogonadism
Vitamin D
Calcium
Therapeutics
Diphosphonates
Calcitonin
Prostaglandins E
Parathyroid Hormone
Osteoblasts
Bone Density
Early Diagnosis
Anti-Inflammatory Agents
Cytokines

Keywords

  • bone metabolism
  • glucocorticoids
  • osteoporosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Glucocorticoid-induced osteoporosis : Pathogenesis, prevention and treatment. / Gulko, P. S.; Mulloy, A. L.

In: Clinical and Experimental Rheumatology, Vol. 14, No. 2, 01.03.1996, p. 199-206.

Research output: Contribution to journalReview article

@article{bf02fda3dd5e43fab79f8d3e19079459,
title = "Glucocorticoid-induced osteoporosis: Pathogenesis, prevention and treatment",
abstract = "Glucocorticoids (GC) are widely used for anti-inflammatory and immunossupressive therapy. Thirty to 50{\%} of GC-treated patients develop osteoporosis. Potential mechanisms of GC-induced osteoporosis (GC-OP) include abnormalities in calcium balance, vitamin D metabolism, parathyroid hormone release and activity, prostaglandin E 2 and cytokine synthesis, interference with c-fos and p-53 expression in osteoblasts, and hypogonadism. Early diagnosis and detection of patients at risk are accomplished with rapid, safe and non-invasive bone density measurements. Preventive measures include maintaining a positive calcium balance, vitamin D supplementation (if indicated) and treatment of hypogonadism. The shortest duration and the smallest doses possible of GC for a particular condition are advisable. For high-risk patients and those with established GC-OP calcitonin or bisphosphonate therapy is recommended.",
keywords = "bone metabolism, glucocorticoids, osteoporosis",
author = "Gulko, {P. S.} and Mulloy, {A. L.}",
year = "1996",
month = "3",
day = "1",
language = "English (US)",
volume = "14",
pages = "199--206",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "2",

}

TY - JOUR

T1 - Glucocorticoid-induced osteoporosis

T2 - Pathogenesis, prevention and treatment

AU - Gulko, P. S.

AU - Mulloy, A. L.

PY - 1996/3/1

Y1 - 1996/3/1

N2 - Glucocorticoids (GC) are widely used for anti-inflammatory and immunossupressive therapy. Thirty to 50% of GC-treated patients develop osteoporosis. Potential mechanisms of GC-induced osteoporosis (GC-OP) include abnormalities in calcium balance, vitamin D metabolism, parathyroid hormone release and activity, prostaglandin E 2 and cytokine synthesis, interference with c-fos and p-53 expression in osteoblasts, and hypogonadism. Early diagnosis and detection of patients at risk are accomplished with rapid, safe and non-invasive bone density measurements. Preventive measures include maintaining a positive calcium balance, vitamin D supplementation (if indicated) and treatment of hypogonadism. The shortest duration and the smallest doses possible of GC for a particular condition are advisable. For high-risk patients and those with established GC-OP calcitonin or bisphosphonate therapy is recommended.

AB - Glucocorticoids (GC) are widely used for anti-inflammatory and immunossupressive therapy. Thirty to 50% of GC-treated patients develop osteoporosis. Potential mechanisms of GC-induced osteoporosis (GC-OP) include abnormalities in calcium balance, vitamin D metabolism, parathyroid hormone release and activity, prostaglandin E 2 and cytokine synthesis, interference with c-fos and p-53 expression in osteoblasts, and hypogonadism. Early diagnosis and detection of patients at risk are accomplished with rapid, safe and non-invasive bone density measurements. Preventive measures include maintaining a positive calcium balance, vitamin D supplementation (if indicated) and treatment of hypogonadism. The shortest duration and the smallest doses possible of GC for a particular condition are advisable. For high-risk patients and those with established GC-OP calcitonin or bisphosphonate therapy is recommended.

KW - bone metabolism

KW - glucocorticoids

KW - osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=0029937161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029937161&partnerID=8YFLogxK

M3 - Review article

VL - 14

SP - 199

EP - 206

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 2

ER -